Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

Impact · against what's priced in

Orion Corporation receives a positive catalyst from Phase 3 DASL-HiCaP trial results showing darolutamide significantly reduces the risk of metastasis or death by 58% in high-risk prostate cancer patients. The strong 95% four-year metastasis-free survival rate enhances the drug's competitive positioning in the ARi market.

ORNBV+0.80

No priced-in read yet